Shanghai Serum Bio-Technology Past Earnings Performance
Past criteria checks 1/6
Shanghai Serum Bio-Technology's earnings have been declining at an average annual rate of -11.4%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 2.2% per year. Shanghai Serum Bio-Technology's return on equity is 4%, and it has net margins of 22.7%.
Key information
-11.4%
Earnings growth rate
-20.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -2.2% |
| Return on equity | 4.0% |
| Net Margin | 22.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Shanghai Serum Bio-Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 194 | 44 | 70 | 34 |
| 31 Mar 24 | 192 | 37 | 77 | 33 |
| 31 Dec 23 | 190 | 39 | 75 | 30 |
| 30 Sep 23 | 191 | 52 | 72 | 28 |
| 30 Jun 23 | 190 | 61 | 77 | 19 |
| 31 Mar 23 | 173 | 63 | 73 | 15 |
| 31 Dec 22 | 174 | 64 | 74 | 15 |
| 30 Sep 22 | 190 | 67 | 75 | 20 |
| 30 Jun 22 | 191 | 68 | 71 | 21 |
| 31 Mar 22 | 211 | 77 | 67 | 25 |
| 31 Dec 21 | 209 | 76 | 63 | 26 |
| 30 Sep 21 | 194 | 70 | 58 | 23 |
| 31 Dec 20 | 186 | 63 | 52 | 23 |
| 31 Dec 19 | 188 | 66 | 60 | 19 |
| 31 Dec 18 | 144 | 42 | 51 | 13 |
| 31 Dec 16 | 96 | 29 | 39 | 0 |
| 30 Sep 16 | 92 | 29 | 38 | 0 |
| 30 Jun 16 | 89 | 29 | 36 | 0 |
| 31 Mar 16 | 83 | 22 | 37 | 0 |
| 31 Dec 15 | 76 | 14 | 38 | 0 |
| 31 Dec 14 | 60 | 7 | 31 | 0 |
Quality Earnings: 688163 has high quality earnings.
Growing Profit Margin: 688163's current net profit margins (22.7%) are lower than last year (32%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688163's earnings have declined by 11.4% per year over the past 5 years.
Accelerating Growth: 688163's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688163 had negative earnings growth (-27.2%) over the past year, making it difficult to compare to the Biotechs industry average (-0.3%).
Return on Equity
High ROE: 688163's Return on Equity (4%) is considered low.